Tumor necrosis factor‐α‐secreting CD16+ antigen presenting cells are effectively removed by granulocytapheresis in ulcerative colitis patients

Sánchez‐García, Joaquín; Serrano‐López, Juana; García–Sánchez, Valle; Alvarez‐Rivas, Miguel A.; Jiménez-Moreno, Rosario; Pérez-Seoane, C; Arroyo, Concepción Herrera; Serrano, Josefina; Dios, Juan Francisco de; Torres-Gomez, A

doi:10.1111/j.1440-1746.2010.06377.x

Cited by 10 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GMA is an extracorporeal therapy using a column filled with cellulose acetate beads, which adsorbs 28.3% of granulocytes, 18.1% of monocytes, and 7.8% of lymphocytes from blood in the column (6). It has been reported that CD16+ myeloid dendritic cells (mDC), activated in ulcerative colitis, are removed by GMA, probably resulting in a reduction in serum TNF-α levels (7). Adsorptive depletion of CD14+/CD16+ mDC may suggest a mechanism for the beneficial effect of GMA in pustular psoriasis (8).…”

Section: Discussionmentioning

confidence: 99%

Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis

Fujisawa¹,

Moriya²,

Shibuya³

et al. 2013

Acta Derm Venerol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis

Fujisawa¹,

Moriya²,

Shibuya³

et al. 2013

Acta Derm Venerol

View full text Add to dashboard Cite

“…Moreover, pDC could induce the differentiation and activation of Treg, thus directly or indirectly inhibit a variety of helper T cells 20 . CD16‐mDC in mDC can secrete TNF‐α factor, and the combination of TNF‐α and TLR2 ligand can differentiate CD16‐mDC into mature DCs with high antigen‐presenting ability 21 . The flow cytometry of NK cell and DCs subsets in our ITP patients was further analyzed.…”

Section: Discussionmentioning

confidence: 99%

Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia

Wang

Ran

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Immune thrombocytopenia (ITP) is well‐known as an antibody‐mediated autoimmune disease, and it is easy to get response but often turns to relapse or refractory. Cyclosporin is a traditional immunosuppressant and had a good effect on ITP patients. In this paper, we retrospectively analyze the immunological characteristics and therapeutic effect of cyclosporin in 220 patients with ITP. Methods All newly diagnosed ITP patients in the Department of Hematology, Tianjin Medical University General Hospital from June 2018 to December 2020 were enrolled and divided into four groups according to the expression of autoantibodies and the occurrence of prodromal infection. The basic data and immune indexes of ITP patients in each group were collected. The clinical immunological characteristics of patients in each group and the therapeutic effect of cyclosporin in each group were analyzed. Results Multi‐autoantibody ITP patients were more likely to have low serum albumin and high gamma globulin, and the ratio of albumin to globulin decreased. In addition, the level of IgA and IgG increased and the level of complement C3 and C4 decreased more frequently than those in other groups. The number of CD3+T lymphocytes, especially CD3+CD4+T lymphocytes, decreased in ANA+ITP patients. The number of CD16+CD56+NK cells, pDC/DC ratio, and pDC/mDC ratio were higher than those in other groups. The expression of IL‐6 and the proportion of CD19+B lymphocytes increased in two groups of ITP patients with abnormal autoantibodies. The patients of pro‐infected group were more likely to suffer from coagulation disorder. After treatment with cyclosporin, the response rate increased and the 3‐month relapse rate decreased in all ITP patients, and the therapeutic effect of patients with high megakaryocyte number was significantly higher than that of patients with low megakaryocyte number. The impact factors that influence the effect of glucocorticoid and(or) IVIG were the number of CD3+CD8+T lymphocytes, CD4/CD8 cell ratio, and the number of CD19+B lymphocytes. The independent impact factor of cyclosporin therapeutic response rate was the number of CD3+T lymphocytes. Conclusions ITP is a heterogeneous disease, recurrence may occur during or rapidly after treatment. Cyclosporine included treatment can improve the effective rate of ITP and reduce the relapse rate within 3 months. The number of CD3+T lymphocytes was the only impact factor that influence the therapeutic effect of cyclosporin in ITP patients.

show abstract

“…GMA has emerged as a potential therapeutic option for refractory IH cases . Its effects are attributed to the elimination of activated neutrophils and monocytes in the peripheral blood …”

Section: Discussionmentioning

confidence: 99%

An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up

et al. 2018

View full text Add to dashboard Cite

Tumor necrosis factor‐α‐secreting CD16+ antigen presenting cells are effectively removed by granulocytapheresis in ulcerative colitis patients

Abstract: The effect of GCAP in peripheral blood APC consisted mainly on a significant depletion of tumor necrosis factor-α secreting CD16-mDC. This finding could suggest a potential mechanism of GCAP beneficial effect that must be confirmed in larger series.

Cited by 10 publications

References 34 publications

Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis

Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis

Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia

An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up

Contact Info

Product

Resources

About